Improvement of the Antioxidant and Antitumor Activities of Benzimidazole-Chitosan Quaternary Ammonium Salt on Drug Delivery Nanogels

Bing Ma,Qing Li,Jingjing Zhang,Yingqi Mi,Wenqiang Tan,Zhanyong Guo

DOI: https://doi.org/10.3390/md22010040

2024-01-12

Marine Drugs

Abstract:The present study focused on the design and preparation of acid-responsive benzimidazole-chitosan quaternary ammonium salt (BIMIXHAC) nanogels for a controlled, slow-release of Doxorubicin HCl (DOX.HCl). The BIMIXHAC was crosslinked with sodium tripolyphosphate (TPP) using the ion crosslinking method. The method resulted in nanogels with low polydispersity index, small particle size, and positive zeta potential values, indicating the good stability of the nanogels. Compared to hydroxypropyl trimethyl ammonium chloride chitosan-Doxorubicin HCl-sodium tripolyphosphate (HACC-D-TPP) nanogel, the benzimidazole-chitosan quaternary ammonium salt-Doxorubicin HCl-sodium tripolyphosphate (BIMIXHAC-D-TPP) nanogel show higher drug encapsulation efficiency and loading capacity (BIMIXHAC-D-TPP 93.17 ± 0.27% and 31.17 ± 0.09%), with acid-responsive release profiles and accelerated release in vitro. The hydroxypropyl trimethyl ammonium chloride chitosan-sodium tripolyphosphate (HACC-TPP), and benzimidazole-chitosan quaternary ammonium salt-sodium tripolyphosphate (BIMIXHAC-TPP) nanogels demonstrated favorable antioxidant capability. The assay of cell viability, measured by the MTT assay, revealed that nanogels led to a significant reduction in the cell viability of two cancer cells: the human lung adenocarcinoma epithelial cell line (A549) and the human breast cancer cell line (MCF-7). Furthermore, the BIMIXHAC-D-TPP nanogel was 2.96 times less toxic than DOX.HCl to the mouse fibroblast cell line (L929). It was indicated that the BIMIXHAC-based nanogel with enhanced antioxidant and antitumor activities and acidic-responsive release could serve as a potential nanocarrier.

pharmacology & pharmacy,chemistry, medicinal

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to reduce the cardiotoxicity of the chemotherapeutic drug Doxorubicin HCl (DOX.HCl) and increase its accumulation at tumor sites. Specifically, the researchers developed a new type of acid - responsive nanogel. By grafting 2 - benzimidazole carboxylic acid (BIM) onto hydroxypropyltrimethylammonium chloride chitosan (HACC) to form BIMIXHAC, and then using ion - cross - linking technology with sodium tripolyphosphate (TPP) to prepare blank nanogels (HACC - TPP and BIMIXHAC - TPP). These nanogels are further used to precisely control the release of DOX.HCl. The main objectives of the study are:

1. **Improve drug encapsulation efficiency and loading capacity**: By designing and preparing the acid - responsive BIMIXHAC nanogel, improve the encapsulation efficiency (EE) and loading efficiency (LE) of DOX.HCl.
2. **Achieve acid - responsive release**: Make the nanogel accelerate the release of DOX.HCl in an acidic environment (such as the tumor microenvironment), thereby increasing the drug accumulation at tumor sites.
3. **Enhance antioxidant and antitumor activities**: By introducing the benzimidazole ring, reduce the free radicals generated by DOX.HCl, thereby enhancing its antitumor effect and reducing cardiotoxicity.
4. **Evaluate in vitro cytotoxicity and biocompatibility**: Evaluate the cytotoxicity of the nanogel on the human lung adenocarcinoma cell line (A549) and the human breast cancer cell line (MCF - 7) by MTT assay, and test its toxicity on the mouse fibroblast cell line (L929) to verify its biocompatibility and potential targeted antitumor treatment ability.

In summary, this study aims to develop a nanogel with acid - responsiveness, high encapsulation efficiency and loading capacity, good biocompatibility and antioxidant activity, in order to improve the therapeutic effect of DOX.HCl and reduce its side effects.